WSE:BML

Stock Analysis Report

BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek

Executive Summary

BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A., a biotechnology company, manufactures and sells medicinal products, medical devices, and laboratory reagents in Poland.

Snowflake

Fundamentals

Mediocre balance sheet and overvalued.

Share Price & News

How has BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

0.8%

BML

2.6%

PL Biotechs

1.1%

PL Market


1 Year Return

-16.4%

BML

-17.0%

PL Biotechs

-3.2%

PL Market

Return vs Industry: BML exceeded the Polish Biotechs industry which returned -17% over the past year.

Return vs Market: BML underperformed the Polish Market which returned -3.2% over the past year.


Shareholder returns

BMLIndustryMarket
7 Day0.8%2.6%1.1%
30 Day-0.2%-2.6%-2.6%
90 Day-2.2%-2.6%-7.7%
1 Year-16.4%-16.4%-16.9%-17.0%-0.3%-3.2%
3 Year12.4%12.4%-12.7%-12.7%11.6%3.6%
5 Year-63.9%-63.9%44.1%42.1%0.2%-11.9%

Price Volatility Vs. Market

How volatile is BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek undervalued compared to its fair value and its price relative to the market?

1.96x

Price to Book (PB) ratio


Share Price vs. Fair Value

Undervalued: BML (PLN0.98) is trading above our estimate of fair value (PLN0)

Significantly Undervalued: BML is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: BML is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.

PE vs Market: BML is unprofitable, so we can't compare its PE Ratio to the Polish market.


Price to Earnings Growth Ratio

Low PEG Ratio: Insufficient data to calculate BML's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: BML is good value based on its PB Ratio (2x) compared to the PL Biotechs industry average (2.2x).


Next Steps

Future Growth

How is BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

16.3%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek performed over the past 5 years?

-11.3%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Earnings Trend: BML is unprofitable, and losses have increased over the past 5 years at a rate of -11.3% per year.

Accelerating Growth: Unable to compare BML's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: BML is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-2.3%).


Return on Equity

High ROE: BML has a negative Return on Equity (-98.44%), as it is currently unprofitable.


Return on Assets

ROA vs Industry: BML is currently unprofitable, so its Return on Assets is negative.


Return on Capital Employed

ROCE Improving: BML is currently unprofitable, so its Return on Capital Employed is negative.


Next Steps

Financial Health

How is BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek's financial position?


Financial Position Analysis

Short Term Liabilities: BML's short term assets (PLN17.8M) do not cover its short term liabilities (PLN28.6M)

Long Term Liabilities: BML's short term assets (17.8M) do not cover its long term liabilities (27.6M)


Debt to Equity History and Analysis

Debt Level: BML's debt to equity ratio (28.8%) is considered satisfactory

Reducing Debt: BML's debt to equity ratio has increased from 26.8% to 28.8% over the past 5 years.


Balance Sheet

Inventory Level: BML has a high level of physical assets or inventory.

Debt Coverage by Assets: BML's debt is covered by short term assets (assets are 2.000780x debt).


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: Whilst unprofitable BML has sufficient cash runway for more than 3 years if it maintains its current positive free cash flow level.

Forecast Cash Runway: BML is unprofitable but has sufficient cash runway for more than 3 years, due to free cash flow being positive and growing by 55.6% per year.


Next Steps

Dividend

What is BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%2.6%markettop25%7.4%industryaverage0.8%forecastin3Yearsn/a

Current dividend yield vs market & industry


Stability and Growth of Payments

Notable Dividend: Unable to evaluate BML's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate BML's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.

Stable Dividend: Insufficient data to determine if BML's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if BML's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of BML's dividend in 3 years as they are not forecast to pay a notable one for the Polish market.


Next Steps

Management

What is the CEO of BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek's salary, the management and board of directors tenure and is there insider trading?

zł185k

CEO Compensation


CEO

Marcin Piróg 0

0yrs

Tenure

zł185,000

Compensation

Mr. Marcin Piotr Piróg serves as Chief Executive Officer and President of Management Board of BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek Spólka Akcyjna. Mr. Piróg served as the President of LOT Polish A ...


CEO Compensation Analysis

Compensation vs. Market: Marcin's total compensation ($USD0.00) is too low to compare against companies of similar size in the Polish market ($USD0.00).

Compensation vs Earnings: Insufficient data to compare Marcin's compensation with company performance.


Insider Trading

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown


Management Team

  • Marcin Piróg

    CEO & President of Management Board

    • Tenure: 0yrs
    • Compensation: zł185.00k
  • Piotr Fic (51yo)

    Member of the Management Board for Operational Matters

    • Tenure: 0.7yrs
  • Katarzyna Krukowoska

    Head Accountant

    • Tenure: 0yrs
  • Wlodzimierz Parzydlo

    CFO & Member of Management Board

    • Tenure: 0yrs
    • Compensation: zł70.00k
  • Grzegorz Stefanski

    Member of the Management Board

    • Tenure: 2.1yrs
    • Compensation: zł43.00k

Board Members

  • Konrad Miterski

    Member of the Supervisory Board

    • Tenure: 0yrs
    • Compensation: zł1.00k
  • Waldemar Sierocki

    Member of Supervisory Board

    • Tenure: 0yrs
    • Compensation: zł1.00k
  • Wiktor Napióra

    Vice Chairman of the Supervisory Board

    • Tenure: 0yrs
    • Compensation: zł93.00k
  • Dariusz Kucowicz

    Member of Supervisory Board

    • Tenure: 11.8yrs
    • Compensation: zł232.00k
  • Piotr Kwasniewski

    Member of the Supervisory Board

    • Tenure: 0yrs
    • Compensation: zł1.00k
  • Jaroslaw Blaszczak

    Chairman of the Supervisory Board

    • Tenure: 0yrs
    • Compensation: zł68.00k
  • Andrzej Szostek

    Supervisory Board Member

    • Tenure: 0yrs

Company Information

BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A.
  • Ticker: BML
  • Exchange: WSE
  • Founded: 1944
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: zł60.891m
  • Shares outstanding: 62.26m
  • Website: https://biomedlublin.com

Location

  • BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A.
  • ul. Uniwersytecka 10
  • Lublin
  • 20-029
  • Poland

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
BMLWSE (Warsaw Stock Exchange)YesCommon Bearer SharesPLPLNJul 2011

Biography

BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A., a biotechnology company, manufactures and sells medicinal products, medical devices, and laboratory reagents in Poland. The company’s prescription drugs  ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/10/14 21:10
End of Day Share Price2019/10/14 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.